{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Premedication&page=7", "query": { "intervention": "Premedication", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 185, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Premedication&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Premedication&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T08:36:39.344Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04963296", "title": "A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Acetaminophen/Paracetamol", "type": "DRUG" }, { "name": "Diphenhydramine hydrochloride", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 303, "start_date": "2021-10-26", "completion_date": "2028-03-13", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 14, "location_summary": "Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04963296" }, { "nct_id": "NCT00103207", "title": "Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2005-10-13", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 157, "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 107 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103207" }, { "nct_id": "NCT04815876", "title": "PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infection" ], "interventions": [ { "name": "Transperineal MRI-guided prostate biopsy", "type": "PROCEDURE" }, { "name": "Transrectal MRI-guided prostate biopsy", "type": "PROCEDURE" }, { "name": "Antibiotic (prophylaxis)", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1040, "start_date": "2021-06-24", "completion_date": "2025-10-11", "has_results": true, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 16, "location_summary": "Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04815876" }, { "nct_id": "NCT02747043", "title": "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "ABP 798", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2016-05-25", "completion_date": "2019-06-28", "has_results": true, "last_update_posted_date": "2022-09-10", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 5, "location_summary": "Encinitas, California • Mount Sterling, Kentucky • Billings, Montana + 2 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Mount Sterling", "state": "Kentucky" }, { "city": "Billings", "state": "Montana" }, { "city": "Zanesville", "state": "Ohio" }, { "city": "Roanoke", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02747043" }, { "nct_id": "NCT01001221", "title": "Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Malignant" ], "interventions": [ { "name": "cabazitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2009-11", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-09-11", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 4, "location_summary": "Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01001221" }, { "nct_id": "NCT04918147", "title": "Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgG4 Related Disease", "IgG4-RD" ], "interventions": [ { "name": "elotuzumab", "type": "DRUG" }, { "name": "placebo for elotuzumab", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "famotidine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2021-10-13", "completion_date": "2024-01-04", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04918147" }, { "nct_id": "NCT05768919", "title": "Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Treatment Period 1", "type": "DRUG" }, { "name": "Treatment Period 2", "type": "DRUG" }, { "name": "Treatment Period 3", "type": "DRUG" }, { "name": "Treatment Period 4a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SignPath Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-03-03", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768919" }, { "nct_id": "NCT01382940", "title": "A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2011-07-26", "completion_date": "2013-01-06", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01382940" }, { "nct_id": "NCT02058511", "title": "Infrared Pupillometry During General Anesthesia to Predict Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Postoperative Pain", "Objective Assessment of Sedation" ], "interventions": [ { "name": "Anesthesia Premedication, Induction and Maintenance", "type": "DRUG" }, { "name": "Pupillometry after administration of anesthetic drugs", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 24, "start_date": "2012-11", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02058511" }, { "nct_id": "NCT01612052", "title": "Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "MRSA - Methicillin Resistant Staphylococcus Aureus Infection" ], "interventions": [ { "name": "Antibiotic Prophylaxis", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CAMC Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 200, "start_date": "2011-05", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2013-02-20", "last_synced_at": "2026-10-20T08:36:39.344Z", "location_count": 1, "location_summary": "Charleston, West Virginia", "locations": [ { "city": "Charleston", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01612052" } ] }